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The use of hyperpolarised 13C-MRI in clinical body imaging
to probe cancer metabolism
Ramona Woitek 1,2,3 and Ferdia A. Gallagher 1,3
Metabolic reprogramming is one of the hallmarks of cancer and includes the Warburg effect, which is exhibited by many
tumours. This can be exploited by positron emission tomography (PET) as part of routine clinical cancer imaging. However, an
emerging and alternative method to detect altered metabolism is carbon-13 magnetic resonance imaging (MRI) following
injection of hyperpolarised [1-13C]pyruvate. The technique increases the signal-to-noise ratio for the detection of
hyperpolarised 13C-labelled metabolites by several orders of magnitude and facilitates the dynamic, noninvasive imaging of the
exchange of 13C-pyruvate to 13C-lactate over time. The method has produced promising preclinical results in the area of
oncology and is currently being explored in human imaging studies. The first translational studies have demonstrated the
safety and feasibility of the technique in patients with prostate, renal, breast and pancreatic cancer, as well as revealing a
successful response to treatment in breast and prostate cancer patients at an earlier stage than multiparametric MRI. This
review will focus on the strengths of the technique and its applications in the area of oncological body MRI including
noninvasive characterisation of disease aggressiveness, mapping of tumour heterogeneity, and early response assessment. A
comparison of hyperpolarised 13C-MRI with state-of-the-art multiparametric MRI is likely to reveal the unique additional
information and applications offered by the technique.
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BACKGROUND
Metabolic reprogramming is a significant hallmark of most
cancers. The Warburg effect is an example of this, using aerobic
glycolysis instead of oxidative phosphorylation to produce ATP,
and can be demonstrated visually in many cancer patients by the
increased uptake of the glucose analogue [18F]2-fluoro-2-deoxy-D-
glucose using positron emission tomography ([18F]FDG-PET)
(Fig. 1).1,2 However, [18F]FDG-PET cannot distinguish the individual
metabolites produced from the breakdown of glucose, or their
cellular compartmentalisation, and provides no direct information
on glycolytic flux or mitochondrial oxidative metabolism. In
addition, the ionising radiation emitted during PET poses a small
potential risk to patients, which is compounded by [18F]FDG-PET
typically being performed in conjunction with computed tomo-
graphy (CT) for localisation and quantification purposes as a
hybrid imaging test: the effective dose of a combined PET/CT is
~11mSv (range 8–24mSv; ref. 3), which equates to approximately
five times the average annual exposure from natural background
radiation (~2.3 mSv; refs. 4,5). The increased risk of both cancer
and heritable effects due to ionising radiation is ~5% per Sievert
(Sv), which is equivalent to ~0.05% for a PET/CT.6 Another
limitation of the technique is that [18F]FDG-PET demonstrates low
sensitivity in a number of cases: in tumours with limited [18F]FDG
uptake, such as prostate cancer;7 in tumours with adjacent high
physiological [18F]FDG uptake, such as brain tumours surrounded
by normal brain tissue; or in cancer of the prostate neighbouring
the bladder.8,9 Furthermore, increased [18F]FDG uptake due to
infection or inflammation limits the specificity of the technique
but can also be seen as a result of immune infiltration in tumours
responding to treatment, thus limiting the accuracy of the
technique for early response assessment.10,11
In contrast with PET, magnetic resonance imaging (MRI) is a
nonionising technique that is used for studying the structure
and function of soft tissues, including tumours.12 Systems that
integrate PET with MRI are increasingly being used for clinical
body imaging in oncology to correlate metabolic findings
with other functional and structural features. PET-MRI has
applications in body regions where MRI is superior to CT for
demonstrating soft-tissue contrast, such as in rectal, prostate,
hepatobiliary and gynaecological cancers, as well as in brain
tumours. Advances in attenuation correction and motion
correction have helped to establish PET-MRI as a hybrid imaging
technology in clinical oncology.13 Furthermore, preclinical data
show that a differential response in pyruvate metabolism and
[18F]FDG uptake might exist following treatment in some
tumour models, suggesting that MRI and PET could have
complementary roles that could be exploited in the setting of
combined PET-MRI.14
One of the major strengths afforded by MRI is the ability to
noninvasively detect and probe the levels of many tissue
metabolites simultaneously and distinguish between them using
MR spectroscopy (MRS): certain nuclei resonate in a magnetic field
at a frequency that is determined by the local chemical
environment. MRS using the proton resonance of hydrogen (1H)
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atoms can facilitate the noninvasive detection, identification and
quantification of numerous biochemical compounds or metabo-
lites, such as choline, lactate and many others. Some examples of
the use of 1H-MRS for detecting phospholipid metabolism,
glycolysis, cellular energetics and altered mitochondrial function
in tumours are provided in Box 1. However, the use of 1H-MRS in
routine clinical practice is largely limited to specific applications in
neuroradiology and prostate cancer, in part due to in the
requirements for specialist data acquisition and analysis methods,
which are not widely available.32,33
Carbon-13 (13C), a nonradioactive form of carbon found at a







































































Fig. 1 Glucose metabolism in cancer and its relevance for metabolic imaging. Cancer cells frequently demonstrate increased levels of
glycolysis including conversion of glucose into pyruvate and subsequently into lactate (the Warburg effect). Consequently, increased import
of glucose into tumour cells is maintained by increased expression of glucose transporters (GLUT). The intravenously injected positron
emission tomography (PET) tracer [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) is similarly taken up via the same transporter and also undergoes
subsequent phosphorylation catalysed by hexokinase; this phosphorylation prevents its subsequent export from the cell. Hyperpolarised
[1-13C]pyruvate can be used to image metabolic alterations further down the glycolytic pathway. Monocarboxylate transporters (MCTs)
mediate its uptake into cancer cells, where it undergoes reduction to [1-13C]lactate catalysed by lactate dehydrogenase (LDH), transamination
to [1-13C]alanine by alanine-aminotransferase (ALT), or irreversible oxidative decarboxylation to acetyl Co-A, a reaction catalysed by pyruvate
dehydrogenase (PDH). During the latter oxidation, the hyperpolarised 13C-label is transferred from the carboxyl (C1) position of pyruvate to
13CO2 and is detectable on spectroscopic imaging as bicarbonate (H
13CO3
−). An alternative fate of [1-13C]pyruvate is carboxylation via
pyruvate carboxylase (PC) to [1-13C]oxaloacetic acid, which can then be metabolised to [1-13C]malate. Any fumarate that is formed through the
reverse fumarase reaction is symmetrical and therefore any subsequent forward exchange via fumarase results in the production of four-
carbon intermediates with the 13C-labelling also present at C4 ([4-13C]malate and [4-13C]oxalacetic acid). The metabolites of this pathway have
been detected using hyperpolarised 13C-MRI in preclinical liver studies;110,111 increased conversion of pyruvate into oxaloacetic acid has been
demonstrated in lung and breast cancer using non-imaging studies, which raises important applications for detecting this reaction more
generally within tumours.112 However, none of these four-carbon intermediates have been detected in cancer using clinical hyperpolarised
13C-MRI. The 13C-label in the C1 position is shown as yellow circles and in the C4 position as red circles. For clarity, enzymatic cofactors and
some of the additional substrates and products have been omitted. Other metabolic alterations relevant for cancer imaging are accumulation
of 2-hydroxyglutarate (2HG) due to mutated isocitrate dehydrogenase (IDH) in the tricarboxylic acid cycle and accumulation of succinate due
to succinate dehydrogenase (SDH) deficiency.
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carbon forms the backbone of many endogenous metabolites,
13C-MRS offers the possibility of noninvasively detecting and
probing many metabolic reactions in vivo. However, conventional
13C-MRS is limited by the spatial and temporal resolution that can
be achieved, particularly in the clinical setting. In this review,
we outline the role for hyperpolarised 13C-MRI, an emerging
technique that increases the signal-to-noise ratio for the detection
of hyperpolarised 13C-labelled metabolites by several orders of
magnitude, focusing on its applications in the area of oncological
body MRI including noninvasive characterisation of disease
aggressiveness, mapping of tumour heterogeneity and early
response assessment.
HYPERPOLARISED MRI AND PYRUVATE METABOLISM
Tumour metabolites, such as choline, lactate, succinate and
fumarate, can be detected using 1H-MRS because they often give
rise to discrete peaks that are present at high concentration, often
in the millimolar range. However, metabolites that occur at low
concentrations, or which generate overlapping resonance peaks
on 1H-MRS, are more difficult to discriminate. By contrast,
metabolite peaks detected using 13C-MRS are easier to separate
as they are more widely dispersed. The sensitivity for detecting
the many metabolic reactions that involve 13C can be significantly
enhanced by the oral or intravenous administration of 13C-
enriched compounds, and this approach has been applied to both
preclinical and clinical research to interrogate a large range of
metabolic pathways. Glycolysis, the tricarboxylic acid (TCA) cycle,
as well as pathways intersecting with these two have been the
most widely studied.34
Hyperpolarisation of 13C is an emerging method that increases
the signal-to-noise ratio by greater than 104-fold over 13C signal
acquired at thermal equilibrium (i.e. nonhyperpolarised).35 The
technique of hyperpolarisation involves increasing the nuclear
polarisation of a molecule, which consequently increases the
available signal that can be acquired using MR. Although
polarisation levels for 13C-pyruvate of as high as 70% have been
reported using experimental systems, current clinical hyperpolari-
sers typically polarise molecules of biological interest, such as
pyruvate, in the range of 20–30% in the liquid state, which
equates to a 105-fold signal enhancement when 13C is imaged at 3
Tesla (T), compared with its thermodynamic polarisation at the
same field strength.36,37
The hyperpolarisation process
Hyperpolarisation utilises the principles of dynamic nuclear
polarisation (DNP) to polarise a frozen solution in the solid state
with subsequent rapid dissolution while preserving polarisation
during the transition into the liquid state for eventual injection
into patients. The process is shown by the schematic in Fig. 2: at
the beginning of the process, endogenous metabolites labelled
with 13C are doped with a free radical (electron paramagnetic
agent, EPA) to facilitate polarisation by providing unpaired
electrons, placed in a magnetic field (typically 3.35–5 T) and
cooled to ~1 K (−272 °C). Microwave irradiation at frequencies
close to the resonant frequency of the electron spin over 1–2 h is
then used to transfer spin polarisation from free electrons to the
13C nuclei in the solid state. Subsequently, the sample is rapidly
dissolved using superheated water and the radical is removed for
patient studies. After having passed suitability checks for use in
patients (e.g. pyruvate concentration, pH, residual EPA concentra-
tion, and temperature), the solution containing the hyperpolarised
13C-labelled molecule is then injected intravenously as quickly as












































Fig. 2 Schematic of the hyperpolarisation process. A solution of
13C-labelled pyruvate is doped with a free radical (electrons show in
blue) to facilitate hyperpolarisation, while placed in a magnetic field
of around 3.35–5 T, cooled to ~1 K (–272 °C), and irradiated with
microwaves. After rapid dissolution and successful quality checks
(temperature, pH etc.), the solution can be injected intravenously.
Box 1
Tumours frequently display altered phospholipid metabolism, which can be
detected using proton (1H) MRS in the form of a prominent signal from choline-
containing compounds that are involved in phospholipid metabolism and
therefore the cellular membranes that form during tumour proliferation.15–17 In
breast cancer, for example, high levels of choline-containing molecules involved
in phospholipid metabolism result in an increased total choline (tCho) signal,
which consists of signals from phosphocholine (PC), glycerophosphocholine
(GPC) and free choline.18,19 An increased tCho signal can be observed in
malignant breast lesions but not in benign lesions or in normal breast tissue, and
has been shown to decrease during neoadjuvant treatment.20–22
As a result of the shift towards increased glycolysis and lactate formation in
cancers due to the Warburg effect, an elevated lactate signal on 1H-MRS is an
indicator of advanced tumour grade and can distinguish cancer recurrence from
treatment-related changes.23,24 However, in breast cancer, high levels of fat in
the peritumoural mammary tissue make lactate detection using 1H-MRS
extremely challenging and this has limited the application of the technique in
routine patient care.25
1H-MRS has been shown to differentiate prostate adenocarcinoma from normal
tissue using the higher (choline+ creatine)/citrate ratio in cancer.26 Metabolites
under the creatine peak (Cr) contribute to energy metabolism while citrate is
found at high abundance in normal prostate tissue.27 However, despite this, 1H-
MRS does not feature in the current Prostate Imaging-Reporting and Data System
(PI-RADS v 2.1), although its use in the future has not been precluded.28
The discoveries of metabolic mutations in some cancers, coupled with
improvements in image/data acquisition, have allowed 1H-MRS to be applied
to the specific detection of tumour-promoting metabolites or oncometabolites.
In body imaging, this approach has been applied to the detection of the
accumulation of intracellular succinate from succinate dehydrogenase (SDH)-
deficient tumours including gastrointestinal stromal tumours, paragangliomas
and phaeochromocytomas.29,30 Changes in succinate concentration over time
have also been demonstrated in patients undergoing therapy.29,30 Moreover, 1H-
MRS has been used to detect the accumulation of fumarate in patients with
hereditary leiomyomatosis and renal cell carcinoma, who harbour mutations in
the fumarate hydratase gene.31
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minimise polarisation loss due to the relatively rapid decay of
signal as a result of the short lifetime of the hyperpolarised signal
(which decays exponentially with a time constant termed T1).
Rapid quality checks, injection, and data acquisition are essential
to allow insight into metabolic exchange rates and enzymatic
activity, as only ~5% of the initial 13C signal remains at three T1s
and <1% at five T1s.
37
Hyperpolarised 13C-pyruvate as a probe
Hyperpolarised 13C is most often incorporated into pyruvate for
preclinical and clinical imaging, as it is an endogenous molecule
with a number of favourable biological, physical and chemical
properties. Pyruvate is a breakdown product of glucose and can
be used to probe several important cellular pathways, as it
occupies a key position in cell metabolism at the branch point
between reduction to lactate in the cytosol and intramitochondrial
oxidative phosphorylation in the citric acid cycle. The low natural
abundance of 13C (1.1%), the gyromagnetic ratio of 13C being a
quarter that of 1H, and the low endogenous concentration of
pyruvate in tissue all mean that detection of the natural
abundance of 13C-pyruvate using 13C-MRI is not feasible in a
clinical setting—hyperpolarised 13C-pyruvate therefore offers a
potential solution to this problem. Pyruvate labelled with 13C in
the carboxyl position ([1-13C]pyruvate) is most frequently used
in vivo for hyperpolarised 13C-MRI, as the time constant for loss of
the hyperpolarised signal (T1) is long at clinical field strengths and
enables metabolism to be studied over 1–2min: the T1 of [1-
13C]
pyruvate is ~60 seconds ex vivo and ~25–30 seconds in vivo.38
Furthermore, low toxicity, rapid intracellular uptake and fast
conversion into observable metabolites with a significant chemical
shift difference, such as lactate, bicarbonate and alanine, make
pyruvate an ideal molecule for clinical use.
Uses of hyperpolarised 13C-pyruvate
Hyperpolarised 13C-pyruvate is injected into patients intravenously
at a concentration of 250mM, which produces an approximate
intravascular concentration of ~1–2mM and a tissue concentra-
tion of ~0.1 mM—similar to the physiological concentrations of
endogenous pyruvate.39,40 Following transport to the tissue of
interest, hyperpolarised 13C-pyruvate undergoes rapid intracellular
uptake mediated by monocarboxylate transporters (MCTs).
Transmembrane transport has been identified in preclinical
studies to be rate-limiting for the conversion of extracellular
pyruvate into lactate, and the importance of MCT1 is supported by
the first clinical studies using hyperpolarised 13C-MRI in breast and
prostate cancer.41–43
The intracellular metabolic fate of pyruvate is outlined in Fig. 1:
the enzyme lactate dehydrogenase (LDH) catalyses the exchange
of hyperpolarised 13C-pyruvate with existing endogenous intra-
cellular lactate, and it is this reaction that will form the focus of this
review. The underlying biological mechanisms that determine the
detection of the hyperpolarised 13C-lactate signal vary between
tumours, and the measured hyperpolarised lactate signal might
depend on a variety of factors, including tissue perfusion,
membrane transport of pyruvate (MCT1) and enzymatic activity
(LDH), as well as the concentration of both the cofactor for the
reaction (NADH) and the product, lactate. For example, if the pool
of endogenous lactate increases, the hyperpolarised 13C-lactate
signal will also increase due to increased 13C-label exchange
between pyruvate and the elevated lactate pool, as has been
demonstrated in many models in vitro.44
The amino acid alanine, also an end-product of glucose
metabolism, is required for protein synthesis and amino acid
transformations, and can also be detected following the injection
of hyperpolarised 13C-pyruvate. Alanine-aminotransferase (ALT)
catalyses the exchange of pyruvate and glutamate to alanine and
α-ketoglutarate. Hyperpolarised 13C-pyruvate has been shown to
label the endogenous alanine pool in normal muscle, liver and
kidney.45–47 Although the endogenous concentration of alanine is
lower in most tumours than in muscle, the formation of
hyperpolarised 13C-alanine has been demonstrated in several
preclinical models of cancer, including pancreatic and prostate
cancer.48,49 Hyperpolarised 13C-alanine has also been detected in
human pancreatic adenocarcinoma (PDAC).50
A third major reaction that can be detected following injection of
hyperpolarised 13C-pyruvate is the irreversible formation of
hyperpolarised 13C-carbon dioxide catalysed by the enzyme
pyruvate dehydrogenase (PDH), which controls pyruvate flux into
the mitochondria. The 13C-carbon dioxide subsequently exchanges
with 13C-bicarbonate through the action of the enzyme carbonic
anhydrase (CA) and, given the greater abundance of bicarbonate
compared with carbon dioxide at physiological pH, it is the
detection of the former that is used to demonstrate significant
PDH activity in vivo. While significant levels of hyperpolarised
13C-bicarbonate can be detected in the brain and the heart
following injection of hyperpolarised 13C-pyruvate,51,52 very little
PDH activity exists in most tumours due to a reduction in oxidative
phosphorylation. However, bicarbonate formation has been
demonstrated in some glycolytic glioblastoma models.53
IMAGE ACQUISITION AND ANALYSIS OF HYPERPOLARISED
13C-MRI DATA
The acquisition techniques used for the first study of metabolic
imaging using hyperpolarised [1-13C]pyruvate in human cancer
were mainly 1D and 2D dynamic MRI at a temporal resolution of 3
seconds using echo-planar spectroscopic imaging (EPSI) to
establish the time course of 13C-pyruvate delivery, and 3D EPSI
single timepoint acquisitions in subsequent patients with a small
field of view (FOV) of 8–10 cm covering the prostate.38 Initial
oncological case reports used dynamic 13C chemical shift imaging
(CSI) in a single slice every 10 seconds in a patient with breast
cancer54 and every 20 seconds for renal cell cancer,55 while 1D
dynamic MRI and 2D single timepoint CSI were acquired in a
patient with pancreatic cancer.50 The first study investigating
hyperpolarised 13C-MRI in different types of breast cancer and
early response assessment in triple-negative breast cancer (TNBC)
used IDEAL spiral CSI at a temporal resolution of 4 seconds for
dynamic metabolic imaging.43,56 Spectral-spatial excitation is
increasingly being used in clinical hyperpolarised 13C-MRI of the
prostate and brain as it increases the signal-to-noise ratio for
downstream metabolites that are less abundant than pyruvate,
while preserving polarisation of the 13C-pyruvate, and can be
combined with echo-planar or spiral k-space trajectories.57–59
Although the analysis of hyperpolarised 13C-MRS or MRI data
acquired at single time points can be accomplished by calculating
the 13C-lactate-to-13C-pyruvate ratio, or by dividing 13C-lactate by
the total signal from all 13C metabolites, this approach does not
take advantage of the dynamic nature of the data generated in
temporally resolved 13C studies. Dynamic hyperpolarised 13C-MRI
confers the potential to provide absolute quantification of
metabolic conversion, regardless of differences in bolus delivery
or polarisation level, by using kinetic modelling to estimate a
pyruvate-to-lactate conversion rate constant (or kPL) or by using
computationally simple approaches, such as the area-under-curve
(AUC) ratio between 13C-lactate and 13C-pyruvate or 13C-lactate
time-to-peak (TTP).60–62 Although the majority of modelling
approaches require the arterial input of pyruvate to be modelled
using an arterial input function, and the time constant for the loss
of the hyperpolarised metabolite signal (T1) to be predefined or
fitted, an inputless kPL fitting method offers the advantage of not
requiring this input function and fits only one or two additional
variables, which simplifies the analysis. For example, the lactate
magnetisation can be fitted (and optionally the T1 of lac-
tate, T1L, which can also be approximated to that of pyruvate),
with the measured pyruvate magnetisation being used as the
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input for the kinetic model at each timepoint.51,61,63 The inputless
method, with its reduced number of fitted parameters, has been
shown to be the most robust approach for data where the signal-
to-noise is low or where there are different bolus characteristics
using both simulated and real data of human prostate cancer, and
is therefore very translatable to the real challenges of many
clinical studies.61
Consistency in the technical acquisition of data at and between
sites is key to the development of the field. Although the
development of faster imaging methods that increase the signal-
to-noise ratio is important for future clinical applications, these new
methods will make comparison between data acquired over time
difficult, as they will compare methods acquired over different
developmental generations. Furthermore, injection rates can vary
between institutions, adding further heterogeneity; indeed, con-
sensus between sites regarding technical acquisition and analysis
would be of great value to this field of research. Very few published
examples of repeatability studies exist42 and more extensive
repeatability and reproducibility research needs to be undertaken.
In conclusion, multicentre studies with homogeneous data
acquisition protocols and analysis pipelines whose protocols
include repeatability and reproducibility studies will be invaluable
for the success of this emerging technique and should be a key
priority for groups and centres focusing their research on
hyperpolarised 13C-MRI.
EARLY-STAGE HUMAN DATA AND IMPLICATIONS FOR
CLINICAL TRANSLATION FROM PRECLINICAL STUDIES
The technique of hyperpolarised 13C-MRI has been applied to a
range of preclinical cancer models over the past 15 years.14,49,59,64–68
The evidence from these studies overwhelmingly indicates an
increased exchange of the hyperpolarised 13C-label between the
injected pyruvate and the endogenous lactate pool in most cancers
that occurs secondary to increased glycolysis as a result of metabolic
reprogramming.66 Indeed, several studies have shown positive
correlations between increased lactate flux on 13C-MRI and tumour
grade and progression in animal models, such as in mouse models
of prostate cancer,48 in models of pancreatic preneoplasia/cancer,49
and in the early detection of Myc-driven liver tumours.66 Two clinical
studies have shown that increased lactate labelling correlates with
increased tumour Gleason grade in prostate cancer and with higher
grade breast cancer, including triple-negative breast cancer.42,43
A second major potential clinical application of hyperpolarised
13C-MRI is the early detection of a successful response to
chemotherapy: a reduction in lactate labelling following treatment
has been demonstrated across a wide range of tumour models
using both chemotherapy and radiotherapy. Early metabolic
changes seen using hyperpolarised 13C-MRI have been demon-
strated between 16 and 48 h after treatment initiation in animal
models of breast cancer, colon cancer and lymphoma14,44,67 and in
patient-derived xenografts of renal cell cancer.68 In some models,
the method has been shown to be more sensitive than [18F]FDG-
PET to early-treatment-related changes.14,68 Preliminary evidence
exists for a reduction in lactate labelling in conjunction with a
successful response to treatment in human prostate cancer,
following androgen ablation and chemotherapy and in breast
cancer after a single cycle of neoadjuvant chemotherapy.56,69
Although the majority of preclinical models have shown a
reduction in lactate labelling following a successful response to
treatment, the changes in 13C-label exchange between pyruvate
and lactate might depend on the type of treatment and
combination of drugs. For example, antiangiogenic drugs might
produce paradoxical effects because of changes in the delivery of
pyruvate and increased hypoxia, which will elevate lactate, and
drugs that affect the availability of NAD(H) will have secondary
effects on LDH, given that it is a cofactor for this enzyme.44,70
Although the preclinical results and early-stage human data
appear promising, the use of hyperpolarised 13C-MRI in routine
clinical care and clinical trials will need to be assessed using larger
patient studies. Below, we describe the current status of the field
and outline the clinical applications in which hyperpolarised 13C-
MRI has the potential to inform clinical decision making.
POTENTIAL CLINICAL APPLICATIONS OF HYPERPOLARISED
13C-MRI
The discussion below focuses on the potential clinical applications
of hyperpolarised 13C-MRI in oncological body imaging, particu-
larly in prostate, renal, breast and pancreatic cancer. The role of
the technique in neurological and cardiological imaging has been
reviewed elsewhere39,71 and so will not be discussed here.
Prostate cancer
Although the widespread use of serum prostate-specific antigen
(PSA) screening has led to a decrease in cancer-related mortality,
there is increasing concern about overdiagnosis and overtreat-
ment of clinically insignificant prostate cancer that has a low risk
of progression during the natural lifetime of the patient.72 One of
the main unmet clinical needs in localised prostate cancer
therefore is the stratification of patients in order to receive the
most appropriate form of management based on the assessment
of tumour aggressiveness e.g. active surveillance (i.e. regular
monitoring until treatment is required) or more interventional
approaches, such as radical radiotherapy and prostatectomy alone
or in combination with antiandrogen therapy and potentially
chemotherapy.73
Several approaches currently exist in routine clinical practice for
predicting prostate tumour aggressiveness. For example, multi-
parametric MRI (mpMRI) plays an important role in ruling out high
Gleason grade disease before treatment and in monitoring the
disease by active surveillance.74,75 However, despite advances in
conventional mpMRI, there is a need to improve both the
sensitivity and specificity of the technique for tumour detection.
The sensitivity and specificity can vary widely from 53% to 100%
and 32% to 97%, respectively; specificity can be lower than 50% for
indeterminate radiological lesions.76–79 For example, a meta-
analysis reported the specificity of mpMRI and prostate imaging-
reporting and data system (PI-RADS version 2) for the detection of
clinically significant prostate cancer as 62%, when using a cut-off
score of ≥4 on PI-RADS, and as low as 29% when using a PI-RADS
score of ≥3 (with sensitivities of 90% and 96%, respectively).78
When reported on a per-lesion basis, sensitivities tended to be
lower, and ranged between 75% and 85%.80,81 Therefore, new
approaches are required to improve the accuracy of disease
characterisation. Assessing tumour metabolism might increase the
accuracy with which the disease is classified as clinically significant,
and 1H-MRS has been used to study tumour metabolism as part of
a multiparametric approach, with increased choline and decreased
citrate detected in more aggressive tumours. However, 1H-MRS is
rarely used clinically and its importance has been de-emphasised
in the most up-to-date version of PI-RADS.82 The use of [18F]FDG-
PET is limited for the assessment of prostate cancer due to low
differential uptake in cancer compared with the normal gland, and
the detection of any accumulation in the prostate is often
contaminated by high levels of tracer in the adjacent urethra
and bladder. In the case of biochemical recurrence (or elevated
PSA levels after curative radical prostatectomy), imaging is used to
detect and locate early recurrence with the aim of providing
curative treatment. mpMRI and targeted PET tracers, such as
18F-fluciclovine and 68Ga-labelled prostate-specific membrane
antigen (PSMA), are currently being investigated for their potential
in detecting early recurrence.83
Hyperpolarised 13C-MRI in patients with prostate cancer has
several potential roles, including: improved patient stratification
by using 13C-lactate labelling to assess aggressiveness; improving
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diagnostic accuracy for the prediction of disease progression in
patients undergoing active surveillance; and locating disease in
the case of biochemical recurrence.84,85
In the seminal first-in-human study of the technology, 31
patients with prostate cancer were successfully injected with
hyperpolarised 13C-pyruvate to assess the safety and feasibility
of the method.38 The results confirmed the preclinical findings
of an increased lactate signal-to-noise ratio (SNR) and an
elevated apparent exchange rate constant for the enzyme LDH
(kPL) in regions of confirmed prostate cancer, compared with the
noncancerous normal gland. In addition, the study provided
preliminary evidence that occult low-grade tumours that were
not visible on conventional proton mpMRI could be detected by
elevated 13C-lactate labelling, indicating potentially increased
sensitivity also for the detection of recurrence when compared
with conventional proton mpMRI. Granlund et al. reported in
2019 that increased lactate labelling correlates with increased
tumour Gleason grade in prostate cancer, a finding that
suggests a potential application of 13C-MRI for the prediction
of disease progression in patients undergoing active surveil-
lance.42 13C-MRI acquired following injection of hyperpolarised
[1-13C]pyruvate in twelve patients with prostate cancer demon-
strated good repeatability, with no significant difference in the
maximum lactate to total carbon signal (Lacmax) between
injections at two time points. There was a significantly higher
Lacmax in the tumours compared with the normal gland, and
lesion detection was increased using hyperpolarised 13C-MRI
compared with 1H-MRI.42
Furthermore, a separate report demonstrated the first clinical case
of using the technique for response assessment in a patient with
metastatic prostate cancer and a serum PSA level of 25.2 ng/ml
(Fig. 3).69 After 6 weeks’ treatment with antiandrogen and
chemotherapy, hyperpolarised 13C-MRI of the prostate revealed a
demonstrable metabolic response, with a return of the lactate
signal-to-noise ratio to normal levels; by contrast, tumour volume on
T2-weighted images on MRI decreased only moderately and the
apparent diffusion coefficient (ADC) on diffusion-weighted imaging
(DWI) showed only a slight increase, indicating only a modest
change in tumour cellularity using this approach. The positive
treatment response was clinically confirmed 6 months later, when
serum PSA levels had decreased and were no longer measurable.
Renal cell carcinoma
The number of early-stage renal cancers that are being detected is
increasing, partly due to the rise in the use of cross-sectional
imaging such as CT and MRI.86 However, despite the early
detection and subsequent treatment of these cancers, there has
been no decrease in disease-specific mortality, which suggests
that a relevant proportion of these patients might receive
overtreatment. Clear cell renal cell carcinoma (ccRCC) has many
features that render it amenable to assessment with hyperpo-
larised 13C-MRI: it is highly glycolytic but well perfused, which is
ideal for imaging using an intravenous metabolic contrast agent
with a short signal lifetime; it is morphologically and genetically
heterogeneous, thus providing a model of metabolic hetero-
geneity; there is increasing evidence that RCC is driven by
metabolic dysregulation, and some renal tumours arise from
mutations in mitochondrial enzymes, making it an ideal model to
study novel tumour metabolism; and alternative methods to
image metabolism, such as [18F]FDG-PET, are limited by contam-
ination from renal excretion of the tracer. Furthermore, as RCC has
a poor prognosis, both new treatments and imaging methods to
monitor response are required.
Hyperpolarised 13C-MRI has the potential to improve treatment
selection in patients with ccRCC by noninvasively predicting
tumour aggressiveness. This hypothesis is supported by evidence
from studies demonstrating that the expression of LDHA, which
encodes a subunit of LDH, correlated positively with tumour grade
and negatively with progression-free survival and overall survi-
val.87 As hyperpolarised pyruvate and13C-MRI assesses a reaction
catalysed by the enzyme LDH, the imaged lactate is likely to
correlate with tumour grade and outcome as well. Noninvasive
prediction of tumour aggressiveness and patient stratification
using current state-of-the-art imaging techniques has poor
a
b









Fig. 3 Hyperpolarised 13C-MRI in a patient with metastatic prostate cancer. Hyperpolarised 13C-MRI in a patient with metastatic prostate
cancer undergoing androgen deprivation therapy before and after 6 weeks of treatment initiation.69 Representative axial T2-weighted (T2W)
anatomic image and corresponding apparent diffusion coefficient (ADC) image, T2W image with an overlaid pyruvate-to-lactate metabolic
exchange rate (kPL) image and corresponding hyperpolarised
13C spectral array are shown. The 52-year-old prostate cancer patient with
extensive high-grade prostate cancer was imaged a before therapy and b 6 weeks after initiation of androgen ablation and chemotherapy.
Before treatment, the region of prostate cancer can be clearly seen (red arrows) as a reduction in signal on the T2W and ADC images, and
increased hyperpolarised lactate and associated kPL on hyperpolarised
13C-MRI. After initiation of androgen deprivation therapy there was a
significant reduction in hyperpolarised lactate and kPL to normal levels, with the prostate volume and ADC showing only a modest response to
treatment. Reprinted from European Urology, volume 72, Aggarwal, R., Vigneron, D. B. & Kurhanewicz, J., Hyperpolarized 1-[13C]-pyruvate
magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer, pages 1028–1029,
Copyright (2017), with permission from Elsevier.
The use of hyperpolarised 13C-MRI in clinical. . .
R Woitek and FA Gallagher
1192
accuracy, and invasive diagnostic approaches suffer from low
sensitivity: biopsy samples have been shown to frequently
undergrade RCCs due to the high degree of intratumoural
heterogeneity, and up to eight biopsy samples are required to
fully evaluate driver mutational status.88 Hyperpolarised 13C-MRI
might therefore also provide a powerful tool to target tissue
sampling and to provide a metabolic readout to be used in
conjunction with the biopsied tissue to minimise undersampling
and undergrading.
Preliminary case reports on the use of dynamic hyperpolarised
13C-MRI in ccRCC have shown promise.55,89 The results have
demonstrated spatial variation in the lactate signal across these
tumours, which corresponds to the ex vivo measurements of
tissue lactate: for example, in multiple tumour biopsy samples
obtained both intraoperatively and from the nephrectomy speci-
mens of patients who had previously undergone hyperpolarised
13C-MRI of the tumour, the tissue lactate concentration measured
using liquid-chromatography mass-spectrometry (LCMS) corre-
lated significantly with the lactate signal-to-noise ratio using
hyperpolarised 13C-MRI, both in intraoperative and post-
nephrectomy samples, thus demonstrating biologic validity of
the method for the first time in humans.55,89
Breast cancer
Neoadjuvant chemotherapy is increasingly gaining importance
in the treatment of early breast cancer and is an important
clinical area in which hyperpolarised 13C-MRI could be used as a
tool for early response assessment, as well as having a
potentially significant impact on clinical decision making. A
2018 meta-analysis has demonstrated that neoadjuvant che-
motherapy increases breast-conservation rates without compro-
mising on distant recurrence, breast cancer survival or overall
survival (OS).90 Pathological complete response (pCR) after
neoadjuvant chemotherapy has been shown to predict
recurrence-free survival (RFS), event-free survival (EFS) and OS,
especially in patients with HER2+ breast cancer and triple-
negative breast cancer (TNBC).91,92 An additional benefit of
neoadjuvant chemotherapy is that it allows any response to
therapy to be assessed in vivo, while the tumour is still
measurable: the clinical response assessment is currently largely
based on monitoring the maximum tumour diameter using
routine clinical radiological examinations.93
However, the prediction of successful response to neoadjuvant
chemotherapy is still a significant clinical challenge. At present
MRI is the most accurate imaging modality for the assessment of
tumour response to neoadjuvant therapy,94 and several meta-
analyses indicate pooled sensitivities for the identification of
residual tumour after completion of preoperative therapy in
patients, that range between 83% and 88% and pooled
specificities of 54–83%.95,96 As in the case of mpMRI of the
prostate, additional approaches are required to improve sensitivity
and specificity. DWI MRI and [18F]FDG-PET have shown promise in
predicting pCR at earlier time points during neoadjuvant
chemotherapy. Identifying nonresponders at this early timepoint
would be highly desirable to allow their management to be
changed (for example, to early surgery) in order to minimise the
risk of metastases from chemoresistant cells and to reduce the
side effects of prolonged but ineffective chemotherapy. It has
been demonstrated that the addition of the ADC measured with
DWI to standard functional tumour volume assessed on contrast-
enhanced MRI showed improvement in the prediction of
treatment response in hormone receptor positive (HR+) and
TNBC, increasing the overall AUC from 0.76 to 0.81 at post-
neoadjuvant chemotherapy.97 When [18F]FDG-PET is performed in
conjunction with MRI, the sensitivity and specificity have reached
up to 100% and 71%, respectively, after only one cycle of
chemotherapy.98 By contrast, 3ʹ-deoxy-3ʹ-[18F]-fluorothymidine
(FLT) PET has been shown to only weakly predict pCR after one
cycle of neoadjuvant chemotherapy.99 Despite initial promising
results for a role for 1H-MRS in monitoring neoadjuvant
chemotherapy, in which an early decrease in tCho indicated a
good response to therapy between 24 h after the initial dose and
after 1–2 cycles,22,100 it has only shown limited predictive power
for pCR or radiological response.32 1H-MRS is also technically
challenging in the setting of a multicentre trial, partly due to long
acquisition times and limited technical support on clinical
scanners and picture archiving and communication systems
(PACS).
New imaging methods are therefore required to predict the
response to therapy sooner and more accurately, which would be
desirable for clinical decision making. Such new methods are
particularly important for combinational and targeted drug
regimens used clinically, and also as companion biomarkers
within clinical trials investigating novel targeted agents such as
poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide
3-kinase (PI3K) pathway inhibitors, mTOR inhibitors such as
everolimus, immune checkpoint inhibitors and cyclin-dependent
kinase (CDK) inhibitors.
Metabolic readouts could enable a very early assessment of
successful response to therapy, given the downstream conver-
gence of these pathways towards alterations in glycolytic
reactions,101 making hyperpolarised 13C-MRI a promising tool to
study metabolic changes in response to therapy. Preclinical
studies have demonstrated that a decrease in label exchange
between pyruvate and lactate can be detected in animal models
of breast cancer as soon as 24 h after initiation of successful
treatment67 and have provided evidence that hyperpolarised
13C-MRI might be more sensitive to very early-treatment-related
metabolic changes than [18F]FDG-PET.14
A first clinical hyperpolarised 13C-MRI study in patients with
early breast cancer demonstrated varying levels of lactate
signal-to-noise ratio and lactate-to-pyruvate ratio across differ-
ent tumour subtypes. Higher lactate signal-to-noise ratio was
observed in the more aggressive and TNBC tumours, which
makes these tumours potential candidates for early response
assessment43 (Fig. 4). These more aggressive tumours are more
likely to undergo neoadjuvant chemotherapy, thus supporting
the potential use of hyperpolarised 13C-MRI in this context.
The metabolic intratumoural heterogeneity observed in TNBC
using hyperpolarised 13C-MRI could make this approach a
potential prognostic imaging biomarker, as several genomic
studies have demonstrated that high levels of intratumoural
heterogeneity are associated with poor prognosis, which might
be due to a decreased immune response.102 The clinical
hyperpolarised 13C-MRI study showed a significant correlation
between the lactate-to-pyruvate ratio and the levels of MCT1,
thus providing a biochemical mechanism for the variation in
lactate labelling in breast cancer.43 Furthermore, the lactate-to-
pyruvate ratio also correlated with tumour volume and the
expression of hypoxia-inducible factor (HIF)-1α, suggesting that
hypoxia might account for the increased lactate labelling in
larger breast tumours.
The first report of assessing treatment response with hyperpo-
larised 13C-MRI in a patient with TNBC showed that an early
response to neoadjuvant chemotherapy could be demonstrated
as a 34% decrease in 13C-lactate labelling after a single treatment
cycle, whereas dynamic contrast-enhanced MRI (DCE-MRI) and
pharmacokinetic modelling did not clearly identify treatment
response at this timepoint.56 Future larger studies are required to
more fully assess the role of the technique in this context.
Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterised by high
morbidity, with 5-year survival rates as low as 10%. More than 50%
of patients are diagnosed with advanced pancreatic cancer and
undergo palliative treatment while only 10–20% are diagnosed
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with early-stage disease that is suitable for potentially curative
surgery.103 The pancreatic tumour niche is characterised by high
interstitial pressure, dense fibrotic stroma, low tumour cellularity,
and reduced vasculature.104,105 To overcome local nutrient
sparsity, PDAC engages in metabolic crosstalk, with tumour cells
deriving some of their nutrients from other intratumoural cell
populations.106 For example, lactate might be secreted by hypoxic
tumour cells and taken up by cancer cells in normoxic portions of
the tumour to fuel proliferation.107
Hyperpolarised 13C-MRI has the potential to improve diagnostic
accuracy when characterising lesions that are incidentally
detected on imaging and could guide management in patients
undergoing neoadjuvant chemotherapy in a similar way to that
described for breast cancer. In a preclinical study in murine
models of pancreatic preneoplasia and invasive cancers, hyperpo-
larised 13C-MRI was been shown to detect preneoplasia based on
an altered alanine-to-lactate ratio and was able to distinguish














































Fig. 4 Hyperpolarised 13C-MRI in a case of triple-negative breast cancer (TNBC) a Coronal T1 3D spoiled gradient echo (SPGR) MRI image.
b Coronally reformatted DCE image at peak enhancement after intravenous injection of a gadolinium-based contrast agent. c Summed
hyperpolarised 13C-pyruvate and d summed hyperpolarised 13C-lactate images. The area of low 13C-pyruvate and 13C-lactate signals in the
centre of the tumour are likely to correspond to an area with low enhancement on DCE. e LAC/PYR map showing intratumoural
heterogeneity. The dominant intratumoural heterogeneity was concordant between the DCE-MRI and hyperpolarised 13C-MRI images and
represents decreased delivery of both the gadolinium-based contrast agent and 13C-pyruvate to the centre of the tumour. f, g Dynamic
hyperpolarised 13C-pyruvate and 13C-lactate images acquired over 15 time points after intravenous injection of hyperpolarised [1-13C]pyruvate
(delay= 12 seconds; temporal resolution= 4 seconds). h Top: 13C metabolite spectrum from a coronal dynamic IDEAL spiral CSI slice covering
the tumour summed over 15 time points; Bottom: The axial image from the equivalent DCE-MRI data was taken at the timepoint of maximum
tumour enhancement. ppm parts per million, IC NST invasive cancer of no specific type. This Figure was reproduced from43 (https://doi.org/























Fig. 5 Hyperpolarised 13C-MRI on a patient with pancreatic cancer. Top row: anatomical axial slice showing the pancreatic tumour (white
arrow) and the exocrine pancreas (purple arrow); the green region of interest outlines the whole pancreas. The ADC is greatly reduced in the
tumour tissue. Bottom row: high [1‐13C]pyruvate, [1‐13C]lactate and [1‐13C]alanine signals were observed in the pancreatic tumour, with
images acquired >30 sec after injection of hyperpolarised [1‐13C]pyruvate. The spectrum acquired in the area of the pancreatic cancer shows
[1‐13C]pyruvate, [1‐13C]lactate and [1‐13C]alanine peaks. Reprinted from50 with permission from John Wiley & Sons.
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semiquantitative parameter.49 In a first clinical report of two
patients with advanced pancreatic cancer who had undergone
several cycles of chemotherapy, the pancreatic adenocarcinoma
could still be distinguished from the adjacent normal tissue based
on elevated lactate levels due to increased levels of glycolysis and
elevated alanine levels (Fig. 5).50 The increase in the levels of
alanine might be due to its secretion by exocrine stellate cells as a
nutrient for adenocarcinoma cells in a hypoxic and nutrient-
deprived tumour environment.108,109
CONCLUSIONS AND FUTURE PERSPECTIVES
Results from preclinical studies indicate that hyperpolarised 13C-
MRI has a number of potential clinical applications: tumour
characterisation based on their metabolic profile; noninvasive
tumour grading; targeting of the most aggressive tumour
regions in the presence of heterogeneity and assessment of
treatment response sooner than is attainable using current
state-of-the-art imaging methods. For hyperpolarised 13C-MRI to
transition from a research tool to a robust and reliable clinical
imaging method for probing cancer metabolism, technical and
biological validation of the procedure is required. Quantitative
and semiquantitative metrics of hyperpolarised 13C-pyruvate
metabolism need to be correlated with invasive results from
tissue analysis to understand the biological drivers for the
imaging measurements. For example, comparing the hyperpo-
larised 13C-lactate signal to the endogenous lactate pool and the
expression of MCTs or LDH will help to reveal the biochemical
mechanisms involved in different tumour types: i.e. to deter-
mine whether membrane transport of the 13C-labelled pyruvate
or enzyme mediated 13C-label exchange between pyruvate and
lactate is the dominant factor in each case. Comparison of
hyperpolarised 13C-MRI with state-of-the-art imaging for cancer
detection will help to establish the added value of imaging
metabolism over conventional anatomical and functional
imaging methods. Repeatability and reproducibility studies are
required to understand how variable the technique is and the
magnitude of the change in tissue metabolism that is required
for detection. Furthermore, harmonisation of acquisition and
analysis methods will aid multicentre trials that are required to
establish the clinical role of the technique.60,61
The field of clinical hyperpolarised 13C-MRI faces many
challenges: the complexity of the clinical kits used for injectable
hyperpolarised pyruvate solutions; the requirements for deter-
mining quality assurance for human use; optimising acquisition,
analysis and quantification of dynamic metabolite measure-
ments due to rapid signal decay; inherent low spatial resolution;
as well as requirements for adequate repeatability and
reproducibility. To accomplish full translation and integration
into clinical cancer imaging, these challenges need to be
overcome and hyperpolarised 13C-MRI needs to be integrated
into clinical trials alongside state-of-the art imaging so that both,
13C-MRI and conventional imaging can be directly compared
with clinical outcome measures such as response and survival.
These trial designs will allow not only allow the clinical utility of
the technique to be evaluated, but also the potential to affect
treatment decisions and patient management. The next step will
be to incorporate hyperpolarised 13C-MRI into treatment
decision-making endpoints within these trials; positive results
from such studies would allow full integration into clinical
care.59 The area of cancer imaging where the evidence for this
translation is most promising is the assessment of early
response; however, the ideal timepoint for assessing these
metabolic endpoints needs to be identified, such that it is early
enough to provide clinical advantage over conventional
imaging but late enough to reliably and specifically identify
nonresponders. Future multicentre trials of the technology will
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